综合治疗方案对肠癌术后异时性肝转移的临床效果观察

目的：探讨不同的手术治疗方法对肠癌术后异时性肝转移的临床效果，分析综合手术疗法的优势，为后续临床研究提供依据。方法：采用回顾性分析的方法对我院2008年12月至2010年12月收治的128例发生肠癌术后异时性肝转移患者的临床资料进行分析。根据治疗方式，将所选病例分为A、B两组。 A组采用病灶切除加化疗的方法治疗；B组采用射频治疗加化疗的方法治疗。比较两组患者治疗的总有效率、病情的总控制率及治疗后的生存率。结果：治疗后，两组患者的临床总有效率和总控制率与治疗前比较差异显著，且A组优于B组，两组比较差异显著且具有统计学意义（P＜0．05）。 A组患者在实施治疗6个月、12个月、24个月、36个月的生存率显著高于B组，差异具有统计学意义（P＜0．05）。结论：采用手术综合法治疗肠癌术后异时性肝转移具有显著的效果，是临床治疗肠癌术后异时性肝转移的可靠选择。

Clinical Effects of Comprehensive Program on the Treatmemt of Metachronous Metastases for the Colorectal Cancer Operation

Objective：To investigate the clinical effects of different methods for the patients with meta-chronous colorectal liver metastases and analyze the advantages of the integrated surgical methods so as to provide a basis for clinical research and practice.Method：A retrospective analysis was performed about the clinical data of 128 patients with metachronous metastases after the surgery of colorectal cancer who were treated in our hospital from Dec.2008 to Dec.2010 .All the selected cases were divided into group A and group B according to the treatment methods.The patients in group A were treated by the resection combined with chemotherapy , while the patients in group B were treated by the RFA combined with chemotherapy . Then the rate of clinical effects, the disease control and the further survival of patients in the two groups were compared and analyzed.Result： After the implementation of different clinical treatment options, the total rate of clinical efficiency and disease control of all the patients in two groups were better than before, and the indexes of the patients in group A were significantly higher than those of the patients in group B.There＇s sta-tistically significant differences（P〈0.05）.The survival rate of patients in group A was significantly higher than that of the patients in group B after the treatment for 6 months, 12 months, 24 months and 36 months. Theres＇statistically significant difference between two groups（P〈0.05）.Conclusion：It is indicates that the comprehensive methods should be a better choice for the treatment of the metachronous colorectal liver metas-tases with the advantage of higher clinical efficacy rate.